TechnologyTargeted Protein Degradation: Designed to destroyTargeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting … more ➔
fundraisingPharmNovo raises €3.5M for phase 2 pain trialSwedish biotech PharmNovo has raised about SEK39m (€3.5m) to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain. more ➔
StrategyAB Science cuts three trials in pipeline resetFrench biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leu … more ➔
partneringRoche drops two Huntington’s programmes from IonisRoche has discontinued two Huntington’s disease programmes after its Ionis-partnered drug tominersen failed to improve patients’ symptoms and a separate candidate raised concerns in animal studi … more ➔
clinical trialAstraZeneca and Ionis miss in key ATTR-CM trialAstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy … more ➔
licensingGSK ends Alector neuroscience deal after trial failuresGSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks. more ➔
fundraisingAlchemab extends Series A with £25m from British Business BankCambridge-based Alchemab Therapeutics has added £25m (€29m) to its Series A financing, taking the round to £109m (€128m) and giving the UK biotech fresh capital to advance its AI-enabled antibody … more ➔
licensingAZ buys ex-China rights to Sino’s COPD drug for $2.1bnAstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona … more ➔
licensingBoehringer licenses PVT virus platform for cancer vaccinesBoehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines. more ➔
Start-upGraph Therapeutics raises $5m to advance I&I pipelineAustria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on … more ➔
